CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL

Trial Overview and Summary

CALiBRe looks at the mechanism of action of idelalisib. Idelalisib has been tested previously in clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL) patients, but the way it works is still unknown. CALiBRe will also investigate how idelalisib affects the rate of growth, and the lifespan, of leukaemia cells in patients with CLL.

Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator:
 Peter Hillmen
Sponsor:   University of Birmingham
Funders:   TAP Bloodwise
Disease Site:
 Chronic Lymphocytic Leukaemia
Trial Type: 
 Clinical Trial of an Investigational Medicinal Product
Open to new sites?
Recruitment start date:
13 July 2015
Anticipated Recruitment end date: 31 Oct 2018
CRCTU Trial Management Team:   Haematology
Trial E-mail Address:

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their healthcare professional or refer to CancerHelp website - see the link under 'More Information'.

Investigators please ensure you have R&D approval for the specified version of the protocol before using as a reference.

Trial Documents (opens a new page)

More Information

Cancer Help (Cancer Research UK) (opens new page)